|
Hemato-oncology / Original Article
Real-world use of polatuzumab vedotin combined with bendamustine and rituximab for patients with relapsed or refractory large B-cell lymphoma
Changgon Kim, Sang Eun Yoon, Hyun-Young Kim, Duck Cho, Junhun Cho, Won Seog Kim, Seok Jin Kim
Korean J Intern Med. 2026;41(2):296-306. Published online March 1, 2026
Background/Aims: Polatuzumab vedotin combined with bendamustine and rituximab (Pola-BR) is a treatment option for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), particularly as bridging therapy before chimeric antigen receptor (CAR) T-cell infusion. However, real-world data regarding..
|